2,312 reports of this reaction
1.5% of all HYDROCODONE BITARTRATE AND ACETAMINOPHEN reports
#10 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #10 most commonly reported adverse reaction for HYDROCODONE BITARTRATE AND ACETAMINOPHEN, manufactured by Amneal Pharmaceuticals LLC. There are 2,312 FDA adverse event reports linking HYDROCODONE BITARTRATE AND ACETAMINOPHEN to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 1.5% of all 153,212 adverse event reports for this drug.
Patients taking HYDROCODONE BITARTRATE AND ACETAMINOPHEN who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for HYDROCODONE BITARTRATE AND ACETAMINOPHEN, but still significant enough to appear in the safety profile.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for HYDROCODONE BITARTRATE AND ACETAMINOPHEN:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 2,312 FDA reports for HYDROCODONE BITARTRATE AND ACETAMINOPHEN. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 1.5% of all adverse event reports for HYDROCODONE BITARTRATE AND ACETAMINOPHEN, making it a notable side effect.
If you experience foetal exposure during pregnancy while taking HYDROCODONE BITARTRATE AND ACETAMINOPHEN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.